Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors
- PMID: 21280201
- DOI: 10.1002/pbc.22989
Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors
Abstract
Background: The optimal frequency of echocardiographic surveillance in asymptomatic childhood cancer survivors exposed to anthracyclines has not been established. We evaluated the effectiveness of performing surveillance echocardiograms according to the Children's Oncology Group's (COG) Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers in survivors ≥1 year from concluding therapy.
Methods: We reviewed all children treated at our institution with anthracycline chemotherapy from 1995 to 2003. We assessed the frequency of abnormal echocardiograms according to risk groups defined in the COG guidelines, and evaluated the risk factors for an abnormal echocardiogram using Cox proportional hazards modeling.
Results: At least one echocardiogram was completed by 469/603 (77.8%) eligible survivors. Mean diagnosis age was 7.7 (SD = 4.6) years. Mean cumulative doxorubicin-equivalent dose was 205 mg/m(2) (SD = 115). Survivors completed 1,013 echocardiograms (median = 2, range =1-10) beyond 1 year after concluding therapy. Seventy-nine (16.8%) survivors had an abnormal echocardiogram at a median of 2.9 years (range 0.01-9.8) from 1 year after concluding therapy. Anthracycline dose >300 mg/m(2) (hazard ratio [HR] 3.00; 95% CI 1.51-5.98), age 1-4 years at treatment (HR 1.89; 95% CI 1.08-3.31) and radiation to a field involving the heart (HR 1.73; 95% CI 1.08-2.76) predicted an increased risk of an abnormal echocardiogram; however, even survivors in the lower COG risk groups demonstrated abnormalities.
Conclusion: Periodic echocardiographic surveillance in childhood cancer survivors can yield abnormalities that require further evaluation. Abnormalities may become evident as early as 1 year after the conclusion of therapy and can impact even those survivors considered to be at low risk.
Copyright © 2011 Wiley-Liss, Inc.
Similar articles
-
Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.Pediatr Blood Cancer. 2010 Apr;54(4):579-84. doi: 10.1002/pbc.22371. Pediatr Blood Cancer. 2010. PMID: 20014238
-
Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.Pediatr Blood Cancer. 2009 May;52(5):631-6. doi: 10.1002/pbc.21913. Pediatr Blood Cancer. 2009. PMID: 19127569
-
Yield of screening echocardiograms during pediatric follow-up in survivors treated with anthracyclines and cardiotoxic radiation.Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26367. Epub 2016 Dec 14. Pediatr Blood Cancer. 2017. PMID: 27966803 Clinical Trial.
-
Exposure to anthracyclines during childhood causes cardiac injury.Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14. doi: 10.1053/j.seminoncol.2006.04.019. Semin Oncol. 2006. PMID: 16781284 Review.
-
Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature.Pediatrics. 2008 Mar;121(3):e705-13. doi: 10.1542/peds.2007-1396. Pediatrics. 2008. PMID: 18310191 Review.
Cited by
-
Treatment, behavioral, and psychosocial components of cardiovascular disease risk among survivors of childhood and young adult cancer.J Am Heart Assoc. 2015 Apr 2;4(4):e001891. doi: 10.1161/JAHA.115.001891. J Am Heart Assoc. 2015. PMID: 25836057 Free PMC article. Review. No abstract available.
-
Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.Lancet Oncol. 2015 Mar;16(3):e123-36. doi: 10.1016/S1470-2045(14)70409-7. Lancet Oncol. 2015. PMID: 25752563 Free PMC article. Review.
-
Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.J Clin Oncol. 2015 Nov 10;33(32):3774-80. doi: 10.1200/JCO.2015.61.5187. Epub 2015 Aug 24. J Clin Oncol. 2015. PMID: 26304888 Free PMC article.
-
Echocardiographic Detection of Cardiac Dysfunction in Childhood Cancer Survivors: How Long Is Screening Required?Pediatr Blood Cancer. 2015 Dec;62(12):2197-203. doi: 10.1002/pbc.25651. Epub 2015 Jul 6. Pediatr Blood Cancer. 2015. PMID: 26146944 Free PMC article. Clinical Trial.
-
A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen.J Drug Assess. 2022 Jun 3;11(1):1-11. doi: 10.1080/21556660.2022.2073101. eCollection 2022. J Drug Assess. 2022. PMID: 35693477 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical